P170 Glycoprotein Expression and Impaired Anthracycline Retention in Chronic Myeloid Leukaemia

References

• Goldman J. M. Management of chronic myeloid leukaemia. Scand. J. Haematol. 1986; 37: 269–280
   PubMedGoogle Scholar
• Tura S., Baccarani M., Zaccaria A. Chronic myeloid leukemia. Haematologica 1986; 71: 169–176
   PubMedGoogle Scholar
• Sokal J. E., Baccarani M., Russo D., Tura S. Staging and prognosis in chronic myelogenous leukemia. Sent. Hematol. 1988; 25: 49–61
   Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., Zurzrock R., Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Sent. Haematol. 1988; 25: 62–73
   Google Scholar
• Kantarjian H. M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691–703
   PubMed Web of Science ®Google Scholar
• Kaye S. B. The multidrug resistance phenotype. Br. J. Cancer 1988; 58: 691–694
   PubMed Web of Science ®Google Scholar
• Weinstein R. S., Kuszak J. R., Kluskens L. F., Coon J. S. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Human Pathol. 1990; 21: 34–48
   PubMed Web of Science ®Google Scholar
• Haber D. A. Multidrug resistance (MDR1) in leukemia: is it time to test?. Blood. 1992; 79: 295–298
   PubMed Web of Science ®Google Scholar
• Damiani D., Michieli M., Michelutti A., Geromin A., Raspadori D., Fanin R., Savignano C., Giacca M., Pileri S., Mallardi F., Baccarani M. Expression of multidrug resistance gene (MDR-I) in human normal leukocytes. Haematologica 1993; 78: 12–17
   PubMedGoogle Scholar
• Michieli M., Michelutti A., Damiani D., Pipan C., Raspadori D., Lauria F., Baccarani M. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leukemia and Lymphoma 1993; 9: 255–264
   PubMed Web of Science ®Google Scholar
• Damiani D., Michieli M., Michelutti A., Melli C., Cerno M., Baccarani M. D-Verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin. Anti-Cancer Drugs 1993; 4: 173–180
   PubMed Web of Science ®Google Scholar
• Hamada H., Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. 1986; 83: 7785–7789
   PubMed Web of Science ®Google Scholar
• Luk C. K., Tannock I. H. Flow cytometry analysis of doxorubicin accumulation in cells from human and rodent cell lines. J. Natl. Cancer Inst. 1989; 81: 55–63
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Sugimoto Y., Hamada H., Roninson I., Okumura M., Adachi K., Morishima Y., Ohno R. Detection of multidrug resistance markers, P-glycoprotein and mdrl mRNA in human leukemia cells. Japanese J. Cancer Res. 1987; 78: 1415–1419
   PubMedGoogle Scholar
• Carulli G., Petrini M., Marini A., Vaglini F., Caracciolo F., Grassi B. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia. Haematologica 1990; 75: 516–521
   PubMedGoogle Scholar
• Kuwazuru Y., Yoshimura A., Hamada S., Lchikawa M., Saito T., Uozumi K., Utsunomiya A., Arima T., Akiyama S. I. Expression of the multidrug transporter. P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis. Brit. J. Haematol. 1990; 74: 24–29
   PubMed Web of Science ®Google Scholar
• Weide R., Dowding C., Paulsen W., Goldman J. The role of the MDR-l/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. Leukemia 1990; 4: 695–699
   PubMed Web of Science ®Google Scholar
• Pileri S. A., Sabattini E., Falini B., Tazzari P. L., Gherlinzoni F., Michieli M. G., Damiani D., Zucchini L., Gobbi M., Tsuruo T., Baccarani M. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathol. 1991; 19: 131–140
   PubMed Web of Science ®Google Scholar
• Drach D., Zhao S., Drach J., Mahadevia R., Gattringer C., Huber H., Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729–2734
   PubMed Web of Science ®Google Scholar
• Chaudhary P. M., Mechtner E. B., Roninson I. B. Expression of the multidrug resistance p-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735–2739
   PubMed Web of Science ®Google Scholar
• Geromin A., Michieli M., Damiani D., Michelutti A., Vigevani E., Signor M., Fanin R., Baccarani M. Cancer chemotherapy does not enhance mdr-associated 170 kd glycoprotein expression in normal blood mononuclear cells. Haematologica 1992; 77: 470–472
   PubMedGoogle Scholar
• Michieli M., Damiani D., Geromin A., Michelutti A., Fanin R., Raspadori D., Russo D., Visani G., Dinota A., Pileri S., Tsuruo T., Grandi M., Baccarani M., Tura S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur. J. Haematol. 1992; 48: 87–92
   PubMed Web of Science ®Google Scholar
• Bruno N. A., Slate D. L. Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug resistant cells. J. Natl. Cancer Inst. 1990; 82: 419–424
   PubMed Web of Science ®Google Scholar
• Berman E., Adams M., Duigou-Osterndort R. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991; 77: 818–825
   PubMed Web of Science ®Google Scholar
• Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267–3276
   PubMed Web of Science ®Google Scholar
• Barr R. D., Fialkow P. J. Clonal origin of chronic myelocytic leukemia. New Engl. J. Med. 1973; 289: 307–309
   PubMed Web of Science ®Google Scholar
• Chaudhary P. M., Roninson I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• List A. F., Spier C. M., Cline A., Doll D. C., Garewal H., Morgan R., Sandberg A. A. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br. J. Haematol. 1991; 78: 28–34
   PubMed Web of Science ®Google Scholar
• Te Boekhorst A. W., De Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., Lbwenberg B., Sonneveld P. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34 acute myeloid leukemia cells. Blood 1993; 82: 3157–3162
   PubMed Web of Science ®Google Scholar
• Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459–62
   PubMed Web of Science ®Google Scholar
• Goldberg J., Vogler R., Grunwald H., Gottlieb A., Bennett J., Gottesman M., Pastan I. MDR1 transcription levels as an indication of resistant disease in acute myelogenous leukaemia. Br. J. Haematol. 1990; 75: 340–345
   PubMed Web of Science ®Google Scholar
• Pirker R., Wallner J., Geissler K., Linkesch W., Haas O. A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 1991; 83: 708–712
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance p-glycoprotein expression in acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug resistance. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Marie J. P., Legrand O., Russo D., Zhou D., Suberville A. M., Zittoun R. Multidrug resistance (MDR) gene expression in acute non-lymphoblastic leukaemia: sequential analysis. Leukemia and Lymphoma 1992; 8: 261–265
   PubMed Web of Science ®Google Scholar
• Marie D. C., Zhou J. P., Suberville A. M., Zittoun R. Relevance of mdrl gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879–885
   PubMed Web of Science ®Google Scholar
• Goasguen J. E., Dossot J. M., Fardel O., Le Mee F., Le Gall E., Leblay R., Le Prise P. Y., Chaperon J., Fauchet R. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases ofde novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–2398
   PubMed Web of Science ®Google Scholar
• Savignano C., Geromin A., Michieli M., Damiani D., Michelutti A., Melli C., Fanin R., Baccarani M. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia. Haematologica 1993; 78: 261–263
   PubMed Web of Science ®Google Scholar